Our observations demonstrating that CD38−/− hearts are resistant to β-adrenoreceptor–associated arrhythmias also reveal the potential of targeting CD38-signaling pathways to treat cardiac disease. This evidence concerns the gene CD38 and cardiac arrhythmia.